ArticleCurrent research in neurobiology2023
Thalamic nuclei changes in early and late onset Alzheimer's disease.
Article in Current research in neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Thalamic Nuclei Atrophy in Type 1 Diabetes Mellitus Across Disease Duration.Journal of magnetic resonance imaging : JMRI · 2026Article
- Magnetic resonance microscopy maps widespread effects of Alzheimer's disease on brain structures and behavior in mice.Nature neuroscience · 2026Article
- Neuronal alkaline phosphatase promotes the spread of Tau-induced pathology, and its blockade prevents neurodegeneration and memory loss.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Article
- Detecting patterns of atrophy in cognitively impaired individuals using portable, low-field MRI.Imaging neuroscience (Cambridge, Mass.) · 2026Article
- Regional patch-based MRI brain age modeling with an interpretable cognitive reserve proxy.Pattern recognition letters · 2026Article
- A deep learning framework for comprehensive segmentation of deep grey nuclei.medRxiv : the preprint server for health sciences · 2025Article
- Disrupted Brain Hierarchical Organization in Alzheimer's Disease Progression.medRxiv : the preprint server for health sciences · 2025Article
- Article
- Atrophy patterns of deep gray matter nuclei in Alzheimer's disease and frontotemporal dementia.Journal of Alzheimer's disease : JAD · 2025Article
- An atlas of age- and sex-related volumetric alterations of grey matter in subcortical regions: The case of 46,111 UK Biobank participants.Mechanisms of ageing and development · 2025Article
- Brain age prediction and early neurodegeneration detection using contrastive learning on brain biomechanics: a retrospective, multicentre study.EBioMedicine · 2025Article
- Molecular and neuropathological determinants of neuronal dysfunction in Alzheimer's disease.bioRxiv : the preprint server for biology · 2025Article
- Evaluating the effective segmentation of human lateral geniculate nucleus.Brain structure & function · 2025Article
- Normative Modeling of Thalamic Nuclear Volumes and Characterization of Lateralized Volume Alterations in Alzheimer's Disease Versus Schizophrenia.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025Article
- Development and validation of a combined clinical and MRI-based biomarker model to differentiate mild cognitive impairment from mild Alzheimer's disease.PCN reports : psychiatry and clinical neurosciences · 2025Article
- The effects of amyloidosis and aging on glutamatergic and GABAergic synapses, and interneurons in the barrel cortex and non-neocortical brain regions.Frontiers in neuroanatomy · 2025Article
- High-power transient 12-30 Hz beta event features as early biomarkers of Alzheimer's disease conversion: An MEG study.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Brain MRI signatures across sex and CSF Alzheimer's disease biomarkers.Brain communications · 2025Article
- A roadmap towards standardized neuroimaging approaches for human thalamic nuclei.Nature reviews. Neuroscience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia worldwide. Increasing evidence points to the thalamus as an important hub in the clinical symptomatology of the disease, with the 'limbic thalamus' been described as especially vulnerable. In this work, we examined thalamic atrophy in early-onset AD (EOAD) and late-onset AD (LOAD) compared to young and old healthy controls (YHC and OHC, respectively) using a recently developed cutting-edge thalamic nuclei segmentation method. A deep learning variant of Thalamus Optimized Multi Atlas Segmentation (THOMAS) was used to parcellate 11 thalamic nuclei per hemisphere from T1-weighted MRI in 88 biomarker-confirmed AD patients (49 EOAD and 39 LOAD) and 58 healthy controls (41 YHC and 17 OHC) with normal AD biomarkers. Nuclei volumes were compared among groups using MANCOVA. Further, Pearson's correlation coefficient was computed between thalamic nuclear volume and cortical-subcortical regions, CSF tau levels, and neuropsychological scores. The results showed widespread thalamic nuclei atrophy in EOAD and LOAD compared to their respective healthy control groups, with EOAD showing additional atrophy in the centromedian and ventral lateral posterior nuclei compared to YHC. In EOAD, increased thalamic nuclei atrophy was associated with posterior parietal atrophy and worse visuospatial abilities, while LOAD thalamic nuclei atrophy was preferentially associated with medial temporal atrophy and worse episodic memory and executive function. Our findings suggest that thalamic nuclei may be differentially affected in AD according to the age at symptoms onset, associated with specific cortical-subcortical regions, CSF total tau and cognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.